Chloramphenicol eye drops are commonly prescribed in concentrations of 0.5-1% in the treatment of infectious conjunctivitis. In terms of ophthalmic solution preparation, the major disadvantage of chloramphenicol consists in its low solubility in water. The solubility is increased by substances that form chloramphenicol-complexes, for example: boric acid/borax or cyclodextrins. Objective: Experimental studies aimed to evaluate the potential advantages of enhancing the solubility and stability of chloramphenicol (API) by molecular encapsulation in b-cyclodextrin (CD), in formulation of ophthalmic solutions buffered with boric acid/borax system. Methods and Results: We prepared four APIb-CD complexes, using two methods (kneading and co-precipitation) and two molar ratio of API/b-cyclodextrin (1:1 and 1:2). The formation of complexes was proved by differential scanning calorimetry (DSC) and the in vitro dissolution tests. Using these compounds, we prepared eight ophthalmic solutions, formulated in two variants of chloramphenicol concentrations (0.4% and 0.5%). Each solution was analyzed, by the official methods, at preparation and periodically during three months of storing in different temperature conditions (4°C, 20°C and 30°C). Conclusions: Inclusion of chloramphenicol in b-cyclodextrin only partially solves the difficulties due to the low solubility of chloramphenicol. The protection of chloramphenicol molecules is not completely ensured when the ophthalmic solutions are buffered with the boric acid/borax system. In terms of ophthalmic solution preparation, the major disadvantage of chloramphenicol as active pharmaceutical ingredient (API) consists in its low solubility in water (1:400) which allows the obtaining of solutions only up to 0.25% (pH = 4.5 to 7.5). In such solutions, chloramphenicol is stable in the pH 2 to 9 range. The solubility of chloramphenicol is increased by substances that form slightly soluble chloramphenicol-complexes, for example: boric acid/sodium tetraborate (borax) or cyclodextrin (CD). Such complexes make possible the achieving of solutions more concentrated in chloramphenicol (0.5-8%) [3, 4] .
Introduction
Chloramphenicol eye drops are commonly prescribed in concentrations of 0.5-1% in the treatment of infectious conjunctivitis, this antibiotic taking the advantage of a broad-spectrum coverage of most gram-positive, gram negative and anaerobic bateria [1, 2] .
In terms of ophthalmic solution preparation, the major disadvantage of chloramphenicol as active pharmaceutical ingredient (API) consists in its low solubility in water (1:400) which allows the obtaining of solutions only up to 0.25% (pH = 4.5 to 7.5). In such solutions, chloramphenicol is stable in the pH 2 to 9 range. The solubility of chloramphenicol is increased by substances that form slightly soluble chloramphenicol-complexes, for example: boric acid/sodium tetraborate (borax) or cyclodextrin (CD). Such complexes make possible the achieving of solutions more concentrated in chloramphenicol (0.5-8%) [3, 4] .
Classically, the eye drops containing 0.5-1% chloramphenicol are prepared using the method of dissolution by mild heating the API in buffer solutions containing boric acid/borax, thus forming chloramphenicol-boric acid/borax complex, in form of sodium salt. Solubility and stability of the resulted complex depend on the pH created in solution by the buffer system. As a consequence: 0.5% chloramphenicol in solution is obtained at pH= 6.8 to 7.2 (solution being stable 10-12 days, stored at room temperature) and 1% chloramphenicol in solution is obtained at pH 8.6 (solution being stable 2-5 days, stored at cool temperature). Boric acid limits the hydrolysis of chloramphenicol in neutral solutions, but at pH > 9 the hydrolytic cleavage of C-Cl bonds (and probably at the amide group, too) occurs rapidly, forming inactive therapeutic products [5, 6] .
Lately, the obtaining of chloramphenicol-cyclodextrins complexes (API-CD) was intended for two purposes: to increase the solubility of API in water and to increase the stability of solution by avoiding the degradation reactions, due to the molecular encapsulation of API in cyclodextrins. b-cyclodextrin (b-CD) and its derivatives (dimethylb-cyclodextrin, hydroxypropyl-b-cyclodextrin etc.) have been used in these cases, whereas the aromatic structure and size of the chloramphenicol molecule are appropriate for this type of cyclodextrins [7, 8, 9, 10] .
In our previous work, we prepared chloramphenicolb-cyclodextrin complexes (API-b-CD), using two technological methods: kneading and co-precipitation, respectively. In both cases, using different analytical methods, we demonstrated the complexes formation in two molar ratios: API-b-CD 1:1 and 1:2, respectively. We also demonstrated, by a microbiological method, the maintaining of therapeutic effectiveness for the 0.5% chloramphenicol eye solutions prepared by dissolving the API-b-CD complexes in water [11] .
The experimental studies presented in this paper aimed to evaluate the potential advantages of enhancing the solu-bility and stability of chloramphenicol by molecular encapsulation in b-cyclodextrin, in formulation of ophthalmic solutions buffered with boric acid/borax system.
Material and methods

Chemicals:
Chloramphenicol (Sigma Aldrich, Germany); b-cyclodextrin (Cyclolab, Hungary); boric acid, sodium tetraborate, phenylmercuric borate, lactose, plysorbate 80, distillated water (pharmaceutical grade); ethanol (p.a.); the used reference industrial product (IND) was: "Sificetina" (1300130LOTTO902), in form of powder and solvent for eye drops (produced by S.I.F.I. SPA, Italia), a product bought from a community pharmacy. -Determination of solubility in water: The sample of 0.010 g was placed into a test tube and portions of 0.1 ml distilled water have been successively added, recording the volume of water in which the sample was dissolved, resulting in a clear solution. -Determination of acidity/alkalinity (pH): The sample (~0.50 g chloramphenicol) was dissolved in 100 ml distilled water and the pH of solution has been determined at 25 °C (Consort-C 831-Multiparameter analyzer). -Determination of the chloramphenicol content (assay): The sample (~0.100 g chloramphenicol) was dissolved in water and then diluted, according with the official method. The diluted solution was analyzed by officinal method, at 278 nm, A 278 nm (1%, 1cm) = 298 (Jasco-V-530 spectrophotometer) [12] .
-Differential scanning calorimetry -DSC [13] : The sample was placed into pierced an aluminum container and subjected to a temperature range of 10-300°C at a heating rate of 5°C/min (Mettler Toledo STAR system). -In vitro dissolution test: was performed by USP-rotating basket method (dissolution apparatus, Erweka model). Experimental conditions: sample quantity depending of the product type (API-100 mg; M 1:1 and C 1:1 -450 mg, respectively; M 1:2 and C 1:2 -800 mg, respectively); 900 ml water at 37°C ±1°C, 100 rpm; solution samples (5 ml), filtered through nylon disc filter (pore of 0.45 mm) and analiyed, after dilution, by spectrophotometer, at 278 nm; quantity of released chloramphenicol was determined by calibration curve method (series of solutions prepared by dissolving 8, 10, 12, 14, 15 mg chloramphenicol in water/methanol 1:1) and expressed as percentage of the initial content. Software for statistical analyzes of dissolution curves: DDSolver as Add-In Microsoft Excel Program [14] .
Preparation and storage of ophthalmic solutions:
-Laboratory products preparation: The solutions were prepared aseptically, respecting the general rules of preparation: boric acid and borax were dissolved in boiling water, chloramphenicol at 50 °C and after cooling the other components (including the chloramphenicol b-cyclodextrin complexes) were dissolved, or added in form of solution (phenylmercuric borate). Each solution was finally completed with water and then packaged in sailed brown glass containers. -Industrial product preparation: The solid part was dissolved in the provided solvent. -Storage of ophthalmic solutions for testing their stability:
After preparation, each ophthalmic solution was divided in 3 portions, sealed in brown glass containers, and then stored for 3 months, protected from light, in different temperature conditions: 4°C ±2°C (refrigerator), 20°C ±5 °C (in a pharmacy store), 30°C ±0.2 °C (oven). Samples were collected periodically, at intervals of one month.
Methods for ophthalmic solutions analysis:
-Aspect: 10.0 ml solution (the sample) was placed in a test tube and compared with 10 ml of water, visualizing the fluid layers on a black background. -Determination of acidity/alkalinity (pH): 30 ml solution (the sample) was analyzed by the same method described above. -Determination of the chloramphenicol content (assay): The sample (~0.025 g chloramphenicol) was diluted with water and the proper dilution was spectrophotometrically analyzed as it was described above. -Comparative analysis: GraphPad Software, statistical methods [15, 16] . One of the objectives of our study was to prepare solid compounds that can be easily used for the preparation of ophthalmic solutions in concentrations of 0.4 or 0.5% chloramphenicol. As a result, we prepared a number of four chloramphenicol-b-cyclodextrin complexes (noted 1-M 1:1 , 2-M 1:2 , 3-C cp1:1 , 4-C cp1:2 ), which were characterized by determination of: chloramphenicol content, solubility in water and pH of the resulting solution ( Figure  1 ). As comparison references, three compounds were used: chloramphenicol (5-API), the powder of an industrial product (6-IND p ) and the b-cyclodextrin (b-CD) used for the preparation of the solid compounds (API-b-CD complexes).
The results of the performed analyzes show that the obtained solid products contain chloramphenicol in different proportions, depending on the preparation method applied, but they show a better solubility than chloramphenicol and also a slightly acidity which remains in range of pH 6-7.
Formation of inclusion complexes and their release capacity:
-Differential scanning calorimetry-DSC (Figures 2-3) :
The thermo-analytical curves of control compounds ( Figure 2) show that: chloramphenicol (5-API) melts at 25 min/which corresponds to a temperature of 150°C; and b-cyclodextrin (b-CD) melts at about 47 min/ 240-245°C. In case of their 1:1 physical mixture, the curve shows distinctly: the moment when b-CD loses its crystallization water-at about 60°C (7-8 min), the moment when chloramphenicol melts-at 150°C (25 min) and the moment when b-CD caramelizes-at 245°C (44-45 min).
The thermo-analytical curves of the fourth chloramphenicol-b-cyclodextrin complexes tested (Figure 3) show in all cases the moments of the b-CD dehydration (at about 6-9 min) and then that of caramelization (at about 50/51 min), while the moment of chloramphenicol melting no longer appears. These behaviors demonstrate the formation of API-b-CD inclusion complexes in all four products obtained in laboratory.
-In vitro release of chloramphenicol from b-cyclodextrin complexes (Figure 4) : The comparative analysis of dissolution profiles show that chloramphenicol dissolves faster from the b-cyclodextrin complexes obtained by kneading method (1-M 1:1 and 2-M 1:2 ) than those obtained by co-precipitation method (3-C 1:1 , 4-C 1:2 ). These observations suggest that co-precipitation determines the formation of more stable complexes. Also, the higher the amount of b-cyclodextrin (2-M 1:2 and 4-C 1:2 ), the faster the chloramphenicol is released. In the case of 3-C 1:1 compound, the chloramphenicol rate release from complex is even similar with that of the chloramphenicol dissolution.
Characteristics of ophthalmic solutions:
-Composition and characteristics determined after preparation: Products in form of ophthalmic solutions were prepared in two variants of chloramphenicol concentration: 0.5% (A-series) and 0.4% (B-series). As references products, we prepared three ophthalmic solutions: with chloramphenicol (API-A, API-B) and the industrial product (IND-B) .
The used excipients were added as: stabilizing agents in form of pH buffer system (boric acid/sodium tetraborate), osmotic agent (lactose), surfactant (polisobate 80) and antimicrobial preservative (phenylmercuric borate). The resulted ophthalmic solutions were coded according to Table I .
The obtained ophthalmic solutions were characterized immediately after preparation. In all cases pH solutions ranged into 7 to 7.5 interval, according to requirements. The appearance of solutions is not clear in every case, due to the differences in solubility. Even if the solubility of chloramphenicol included in b-cyclodextrin is increased, the solubility of complexes (especially of those with higher amounts of b-CD, 1:54 water soluble) still remains a limiting factor if concentrations of 0.4-0.5 chloramphenicol are intended.
In all cases, the chloramphenicol concentrations determined after solutions preparation were situated in the required limits of ±10% of the declared content, namelly: 0,45-0,55% (series A) and 0,36-0,44% (series B).
-Influence of storing conditions on the stability:
Each formulation was then stored for three months in different temperature conditions (4°C, 20°C and 30°C, respectively) and their quality determined periodically after every month. During the three months of storage, pH of solutions was maintained without significant variations, excepting some 0.5% solutions prepared with cyclodextrins complexes in which pH reached to 7.6, but not correlated to temperature. The variation of active ingredient amounts during the storage of solution in different conditions of temperature and the statistical significance of implied variables influences are summarized in Figure 5 and Table II. The results presented in Figure 5 show that the amount of chloramphenicol is variable in solutions during the three months of storage, regardless of temperature. Even so, the solutions prepared with compound 2-M 1:2 (2-A and 2-B) appears to be more stable, especially at lower concentration of chloramphenicol (0.4%-in 2-B). This observation is more valuable, considering that, according to the results presented in Figure 6 , the storage conditions significantly affect the amount of chloramphenicol in case of series-B of ophthalmic solutions.
Conclusions
Inclusion of chloramphenicol in b-cyclodextrin only partially solves the difficulties due to the low solubility of chloramphenicol when the preparation of 0.4-0.5% chloramphenicol ophthalmic solutions is intended. The chloramphenicol-b-cyclodextrin prepared by kneading method in molar ratio of 1:2 could be useful, especially for up to 0.4% chloramphenicol solutions. The protection of chloramphenicol by molecular encapsulation in b-cyclodextrin is not completely ensured when the ophthalmic solution is buffered with the boric acid/borax system.
